Pharmaceutical companies that make slight modifications to their products to obstruct generic competitors engage in exclusionary conduct and should be banned, the Federal Trade Commission argued in a brief filed in...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: